Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Neuroophthalmol. 2019 Jun;39(2):191–199. doi: 10.1097/WNO.0000000000000760

Figure 3. ST266 treatment reduces RGC loss in EAE optic neuritis.

Figure 3.

(A) RGC counts 56 days post-immunization were significantly (***p<0.001) decreased in the eyes of PBS- (N=12) or HSA-treated EAE mice (N=12) compared with control mice (N=8). EAE mice that received once daily doses of intranasal ST266 from day 15 to 30 (N=12), showed no significant preservation of RGCs whereas twice daily ST266 given only from day 15-30 (N=12) did promote a significant increase (@p<0.05) in RGC survival. EAE mice that received either once (N=12) or twice daily (N=12) intranasal doses of ST266 continuously from day 15 to 56 showed a significant (@@@p<0.001) preservation of RGC numbers by day 56 compared with PBS- or HSA-treated EAE mice. (B) Representative images show RGCs (green) in one retina from each group (original magnification X40).